Literature DB >> 20087677

Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers.

David L Eisenberg1, Catherine Stika, Ami Desai, David Baker, Kathleen J Yost.   

Abstract

BACKGROUND: The majority of women prescribed category D or X medications may not receive adequate contraceptive counseling or a reliable contraceptive method. Physicians who prescribe potentially teratogenic medications have a responsibility to provide women with contraceptive counseling, a method of highly-effective contraception, or both.
OBJECTIVE: Investigate the knowledge, beliefs and barriers of primary care physicians toward providing adequate contraception to women taking potential teratogens. DESIGN & PARTICIPANTS: Self-administered confidential survey of primary care internal medicine physicians at an urban, academic medical center. MEASUREMENTS: Knowledge of potential teratogenic medications and contraceptive failure rates was assessed. Participants' beliefs about adequacy of their medical education, practice limitations and attitudes toward improving provision of contraception to women on potential teratogens were assessed.
RESULTS: One hundred and ten physicians responded (57.3%). Nearly two-thirds (62.3%) of participants had cared for reproductive aged women taking category D or X medications in the past year. The mean percent of correctly identified category D or X medications was 58.4% (SD 22.1%). The mean percent correct for knowledge of published contraceptive failure rates was 64.6% (SD 23.1%). Most respondents (87.6%) felt it is the responsibility of primary care physicians to provide contraception. Time constraints were reported to be somewhat or very limiting by 61.3% and over half felt medical school (63.2%) or residency (58.1%) inadequately prepared them to prescribe or counsel about contraceptives.
CONCLUSIONS: Primary care physicians commonly encounter reproductive age women taking category D or X medications, but may lack sufficient knowledge and time to counsel about potential teratogens and contraception to prevent fetal exposure to these drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087677      PMCID: PMC2842551          DOI: 10.1007/s11606-009-1215-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  20 in total

1.  National patterns of medication use during pregnancy.

Authors:  Euni Lee; Mary K Maneno; Leah Smith; Sheila R Weiss; Ilene H Zuckerman; Anthony K Wutoh; Zhenyi Xue
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-08       Impact factor: 2.890

Review 2.  Methodologies for improving response rates in surveys of physicians: a systematic review.

Authors:  Jonathan B VanGeest; Timothy P Johnson; Verna L Welch
Journal:  Eval Health Prof       Date:  2007-12       Impact factor: 2.651

3.  Preventing medication errors: a summary.

Authors:  David W Bates
Journal:  Am J Health Syst Pharm       Date:  2007-07-15       Impact factor: 2.637

4.  Abortion in the United States: incidence and access to services, 2005.

Authors:  Rachel K Jones; Mia R S Zolna; Stanley K Henshaw; Lawrence B Finer
Journal:  Perspect Sex Reprod Health       Date:  2008-03

Review 5.  Medications in pregnancy and lactation: Part 2. Drugs with minimal or unknown human teratogenic effect.

Authors:  Catalin S Buhimschi; Carl P Weiner
Journal:  Obstet Gynecol       Date:  2009-02       Impact factor: 7.661

Review 6.  Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.

Authors:  Margaret A Honein; Jill A Lindstrom; Sandra L Kweder
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Contraceptive counseling in managed care: preventing unintended pregnancy in adults.

Authors:  Carol S Weisman; Deidre Spicer Maccannon; Jillian T Henderson; Emily Shortridge; Camille L Orso
Journal:  Womens Health Issues       Date:  2002 Mar-Apr

8.  Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.

Authors:  Eleanor Bimla Schwarz; Debbie A Postlethwaite; Yun-Yi Hung; Mary Anne Armstrong
Journal:  Ann Intern Med       Date:  2007-09-18       Impact factor: 25.391

Review 9.  Medications in pregnancy and lactation: part 1. Teratology.

Authors:  Catalin S Buhimschi; Carl P Weiner
Journal:  Obstet Gynecol       Date:  2009-01       Impact factor: 7.661

10.  Trends in primary care clinician perceptions of a new electronic health record.

Authors:  Robert El-Kareh; Tejal K Gandhi; Eric G Poon; Lisa P Newmark; Jonathan Ungar; Stuart Lipsitz; Thomas D Sequist
Journal:  J Gen Intern Med       Date:  2009-04       Impact factor: 5.128

View more
  15 in total

Review 1.  Pregnancy and isotretinoin therapy.

Authors:  June Seek Choi; Gideon Koren; Irena Nulman
Journal:  CMAJ       Date:  2013-01-07       Impact factor: 8.262

2.  Using the electronic medical record to refer women taking category D or X medications for teratogen and contraceptive counseling.

Authors:  Sheila K Mody; Jennifer Wu; Marla Ornelas; Colleen Kernahan; Elizabeth Salas; Kelly Kao; Robert Felix; Christina Chambers
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-06-23

3.  Promoting safe prescribing in primary care with a contraceptive vital sign: a cluster-randomized controlled trial.

Authors:  Eleanor Bimla Schwarz; Sara M Parisi; Sanithia L Williams; Grant J Shevchik; Rachel Hess
Journal:  Ann Fam Med       Date:  2012 Nov-Dec       Impact factor: 5.166

4.  Primary care physicians' perceptions of rates of unintended pregnancy.

Authors:  Sara M Parisi; Shannon Zikovich; Cynthia H Chuang; Mindy Sobota; Melissa Nothnagle; Eleanor Bimla Schwarz
Journal:  Contraception       Date:  2011-12-15       Impact factor: 3.375

5.  Using the electronic medical record to assess contraception usage among women taking category D or X medications.

Authors:  Sheila K Mody; John Paul Farala; Jennifer Wu; Robert Felix; Christina Chambers
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-08-25

6.  Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists.

Authors:  Molly M Lynch; Jacqueline B Amoozegar; Emily M McClure; Linda B Squiers; Cheryl S Broussard; Jennifer N Lind; Kara N Polen; Meghan T Frey; Suzanne M Gilboa; Janis Biermann
Journal:  Qual Health Res       Date:  2017-10-03

7.  The Fertility Management Experiences of Australian Women with a Non-communicable Chronic Disease: Findings from the Understanding Fertility Management in Contemporary Australia Survey.

Authors:  Sara Holton; Aberaami Thananjeyan; Heather Rowe; Maggie Kirkman; Lynne Jordan; Kathleen McNamee; Christine Bayly; John McBain; Vikki Sinnott; Jane Fisher
Journal:  Matern Child Health J       Date:  2018-06

8.  Contraceptive methods and informed consent among women receiving medications with potential for adverse fetal effects: a Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) region study.

Authors:  Rex W Force; Gina A Keppel; Janelle Guirguis-Blake; Debra A Gould; Chris Vincent; Kavitha Chunchu; Robert M Monger; John T Holmes; Jacintha Cauffield; Laura-Mae Baldwin
Journal:  J Am Board Fam Med       Date:  2012 Sep-Oct       Impact factor: 2.657

9.  Contraceptive Procedures in Internal Medicine Clinics and Resident Education: a Qualitative Study of Implementation Methods, Barriers, and Facilitators.

Authors:  Rachel S Casas; Christine A Prifti; Alexandra E Bachorik; Heather Stuckey; Mindy Sobota; Cynthia H Chuang; Carol S Weisman
Journal:  J Gen Intern Med       Date:  2021-05-06       Impact factor: 5.128

10.  Counseling of female veterans about risks of medication-induced birth defects.

Authors:  Eleanor Bimla Schwarz; Kristin Mattocks; Cynthia Brandt; Sonya Borrero; Laurie C Zephyrin; Harini Bathulapalli; Sally Haskell
Journal:  J Gen Intern Med       Date:  2013-07       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.